Portfolio company
Sameric Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops protein-based biologics for patients with high unmet medical needs by in-licensing biology and advancing it to clinical proof of concept.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Protego Biopharma
This biotechnology company develops small molecule therapies for patients with systemic amyloid diseases and other protein misfolding disorders.
Attovia Therapeutics
The company develops biparatopic biologics to treat patients with immune-mediated diseases and cancer through a modular protein design platform.
EpiBiologics
This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.
SynsoryBio
SynsoryBio develops protein therapeutics designed to sense specific disease markers and activate only at targeted tissues to treat cancer and autoimmune disorders.
Laigo Bio
This company develops bispecific antibody therapies that remove disease-causing membrane proteins to treat patients with cancer and autoimmune disorders.
Fable Therapeutics
The company develops protein-engineered biologics using machine learning to treat patients with obesity and metabolic diseases.
BYOMass
This company develops biologic and small molecule drugs targeting the TGF-beta superfamily to treat metabolic, fibrotic and age-related diseases for patients with unmet needs.